Skip to main content

Terminal Peptide Modifications

What Are Acetylation and Amidation?

Chemically synthesized peptides come with free termini unless you ask otherwise: a positively charged amino group at the N-terminus and a negatively charged carboxyl group at the C-terminus. A protein does not present its internal sequences that way. N-terminal acetylation and C-terminal amidation remove those two artificial charges, and that one change affects stability, solubility and biological relevance together.

On the left, a peptide with a free N-terminal amino group carrying a positive charge and a free C-terminal carboxyl group carrying a negative charge, with aminopeptidase and carboxypeptidase attacking the two ends. On the right, the same peptide acetylated at the N-terminus and amidated at the C-terminus: both terminal charges removed and both exopeptidases blocked.
A peptide cut out of a protein has two charges the parent protein never had, one at each end. Capping removes them — and incidentally closes the two doors that exopeptidases come in through.

What each modification does

N-terminal acetylationC-terminal amidation
Chemical changeFree α-amino group becomes an acetamideFree α-carboxyl group becomes a primary amide
Charge effectRemoves the terminal positive chargeRemoves the terminal negative charge
Protease effectSlows digestion by aminopeptidasesSlows digestion by carboxypeptidases
Ordering code{Ac}{NH2}

Why it matters for biological relevance

If your peptide comes from the middle of a protein, the residues on either side of it continue in the parent. A free charged terminus is an artefact of having cut the sequence out, and it sits exactly where the chain used to carry on. Capping both ends is the closest a linear peptide gets to presenting that region the way the protein does, which is why terminally modified peptides are the usual choice for functional studies, enzyme assays and anything where biological activity is the readout.

The effect is not merely theoretical. End-capped blocker peptides are routine in ion-channel work: an amidated analogue of the sea anemone peptide ShK is a potent and selective blocker of the Kv1.3 channel,1 and the acetylated, amidated peptide acetyl-KIFMK-amide was used to probe the inner cavity of cardiac sodium channels.2 In both cases the capped form is the one that works as a tool.

The trade-off: solubility usually drops

Removing two charges makes the molecule less polar. For a peptide that was already marginal — long, hydrophobic, or rich in beta-sheet-forming residues — capping can be the difference between dissolving and not. This is the single most common surprise with terminal modification, and it is worth planning for rather than discovering on the day the vial arrives.

Both must be requested before synthesis. Amidation requires starting from an amide resin, and acetylation is carried out on the resin before cleavage. In practice neither is added to a finished peptide: C-terminal amidation is normally designed in by starting on an amide resin, and acetylation is done on resin before cleavage. Post-synthetic routes to both do exist, but on a cleaved peptide they are hard to control — acetylation competes with lysine and other nucleophilic side chains, and amidating a free C-terminal acid selectively is harder still — so for practical purposes a change of terminal chemistry means remaking the peptide. If you are undecided, say so when ordering and we will discuss it before the synthesis starts.

When to cap, and when not to

SituationRecommendation
Peptide taken from inside a protein sequence, used for function or activityCap both ends. This is the standard choice.
The peptide really is the protein's own N- or C-terminusLeave that end free. The charge is genuine, not an artefact.
Already poorly soluble, hydrophobic or aggregation-proneExpect solubility to drop further. Consider capping one end only, or adding a solubilising tag.
Quantitative assay across several peptidesKeep the terminal state identical across the whole set, or the comparison is confounded.
ELISA and binding assaysCapping removes the influence of terminal charge on binding, which usually makes the readout cleaner.
Exopeptidase-containing media, serum or cell cultureCap both ends. This is where the stability benefit is largest.

Related terminal and side-chain modifications

Acetylation and amidation are the two we supply at no additional cost, but they sit in a wider family of terminal chemistry: formylation, succinylation, benzyloxycarbonyl and Boc protection, fatty-acid caps from butyric through palmitic and stearic acid, and C-terminal groups such as aldehyde, alcohol, AMC, pNA and chloromethylketone used in protease substrates. The full list with ordering codes is on the peptide modifications page.

What to send for a quote

  • The sequence, and whether each terminus should be free or capped
  • Whether the peptide is an internal fragment or a genuine protein terminus
  • The assay it is going into, especially if serum or cell culture is involved
  • Any other modifications or labels, and where they sit
  • Purity level and quantity

Quotation

Please email your project details to sales@lifetein.com or use our online quotation form. If you are not sure whether to cap, send the sequence and the assay and we will tell you what we would do.

Further reading

Common questions

What do N-terminal acetylation and C-terminal amidation actually change?
Acetylation converts the free alpha-amino group into an acetamide, removing the terminal positive charge. Amidation converts the free alpha-carboxyl group into a primary amide, removing the terminal negative charge. Together they make an internal protein fragment resemble the parent chain, and they slow digestion by aminopeptidases and carboxypeptidases respectively.
Can acetylation or amidation be added to a peptide I already have?
No. Amidation requires starting the synthesis on an amide resin, and acetylation is performed on the resin before cleavage. Both must be specified when ordering; adding them later means remaking the peptide.
Will capping the termini affect solubility?
Usually it lowers it, because two charged groups have been removed and the molecule is less polar. For sequences that are already hydrophobic or aggregation-prone this can be significant, so it is worth planning for before synthesis rather than discovering it in the vial.
Should every peptide be capped at both ends?
No. Cap both ends when the peptide is taken from inside a protein, since the free charges are then artefacts of cutting the sequence out. Leave a terminus free when it is genuinely the protein's own N- or C-terminus. And keep the terminal state consistent across a set of peptides being compared quantitatively.

References

  1. Chang SC, et al. A C-terminally amidated analogue of ShK is a potent and selective blocker of the voltage-gated potassium channel Kv1.3. FEBS Letters 2012;586(22):3996–4001. doi:10.1016/j.febslet.2012.09.038
  2. Acetyl-KIFMK-amide and the inner cavity of cardiac sodium channels. Biochemical and Biophysical Research Communications 2005;329(2):780–788. PMID 15737654

Sequences supplied by customers are treated as confidential and are never disclosed or reused.

All LifeTein peptides are supplied for laboratory research use only. They are not for human or veterinary use, and not for diagnostic or therapeutic use.